4 Analysts Have This To Say About Stericycle
Portfolio Pulse from Benzinga Insights
Stericycle (NASDAQ:SRCL) has seen varied analyst opinions over the past three months, with recent evaluations showing a positive trend in price targets. The average 12-month price target is now $62.25, marking a 14.22% increase from the previous average of $54.50. Analysts from Wells Fargo, RBC Capital, Stifel, and Truist Securities have all raised their price targets, reflecting optimism about the company's performance. Despite a -2.73% decline in revenue growth for the last quarter of 2023, Stericycle's financial indicators such as net margin, ROE, and ROA outperform industry averages, suggesting strong profitability and financial health.
March 01, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stericycle has received positive adjustments in analyst ratings and price targets, with a notable average price target increase to $62.25. Despite a recent revenue decline, the company's strong financial health indicators suggest resilience and potential for growth.
The positive adjustments in analyst ratings and price targets reflect growing confidence in Stericycle's market position and financial health. Despite the short-term revenue decline, the company's strong profitability and financial indicators, such as net margin, ROE, and ROA, suggest it is well-positioned for future growth. This analysis is based on the recent actions of analysts from reputable firms and the company's financial performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100